Skip to content

CoCo in COPD treatment: evaluation of use, satisfaction and clinical effects

CoCo in COPD treatment: evaluation of use, satisfaction and clinical effects - CoCo COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35348
Enrollment
30
Registered
2011-10-04
Start date
2012-01-09
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease COPD

Interventions

The CoCo application is a technology-supported care service for self-management of COPD exacerbations and for promotion of an active lifestyle. The application consists of three modules: 1) activity

Sponsors

Revalidatiecentrum Het Roessingh
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - a clinical diagnosis of COPD according to the GOLD criteria - no exacerbation in the month prior to enrolment - >=3 exacerbations or one hospitalization for respiratory problmens in the two years preceeding study entry - (ex)smoker - age>40 years - post-bronchodilator FEV1 25-80% of predicted - able to understand and read Dutch - internet access at home

Exclusion criteria

Exclusion criteria: - serious other disease with a low survival rate -other diseases influencing bronchial symptoms and/or lung function (e.g. cardiac insuficiency, sarcoidosis) - severe psychiatric illness - uncontrolled diabetes mellitus during a COPD exacerbation in the past or a hospitalization for diabetes mellitus in the two year preceding the study - need for regular oxygen therapy (>16 h per day or pO2

Design outcomes

Primary

MeasureTime frame
The CoCo application will be evaluated among patients in terms of use of the application (registered by system), satisfaction with the application (UTAUT), satisfaction with received care (CSQ), and quality of care (RATER).

Secondary

MeasureTime frame
Outcome measures to evaluate the clinical effects are: exacerbations (number, duration), amount of activity (accelerometer, BPAQ), exercise tolerance (6MWT), fatigue (MFI-20), health status and symptoms (CCQ), and quality of life (EQ-5D).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)